Timing of iodine-123 scintigraphy following use of recombinant human thyrotropin in differentiated thyroid carcinoma.

A 34-year-old female with a history of multifocal papillary thyroid carcinoma underwent a rhTSH-stimulated iodine-123 (I-123) scan at 6 months postthyroidectomy to determine both thyroid remnant uptake and breast uptake prior to I-131 ablation. Assessment occurred 6 months after cessation of breast feeding. Imaging at 4 hours after I-123 administration showed no uptake in the thyroid bed; however, imaging at 24 hours revealed a single focal area of residual functioning thyroid tissue in the thyroid bed, a finding confirmed on post-I-131 ablation scanning. This suggests that scanning should be delayed until at least 24 hours after radioiodine administration, when using rhTSH-stimulated

[1]  M. Brzozowska,et al.  Timing and Potential Role of Diagnostic I-123 Scintigraphy in Assessing Radioiodine Breast Uptake Before Ablation in Postpartum Women With Thyroid Cancer: A Case Series , 2006, Clinical nuclear medicine.

[2]  Markus Luster,et al.  Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  M. Luster,et al.  Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  A. Alavi,et al.  Comparison of I-123 and I-131 for Whole-Body Imaging After Stimulation by Recombinant Human Thyrotropin: A Preliminary Report , 2003, Clinical nuclear medicine.

[5]  R. Cavalieri,et al.  I-123 Diagnostic Thyroid Tumor Whole-Body Scanning with Imaging at 6, 24, and 48 Hours , 2002, Clinical nuclear medicine.

[6]  A. Alzahrani,et al.  123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer: comparison with post 131I therapy whole body scanning. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  A. Alavi,et al.  Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer , 2001, Clinical nuclear medicine.

[8]  A. Alavi,et al.  Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.